- The University of Oxford 's Oxford Vaccine Group has vaccinated the first volunteer in the world's inaugural clinical trial for a vaccine against the Bundibugyo strain of Ebola .
- This marks the first human administration of the ChAdOx1 BDBV vaccine, which was developed by Oxford scientists using the same technology as the Oxford/AstraZeneca Covid-19 vaccine.
- Bundibugyo has been tearing through the Democratic Republic of Congo, with 3,262 confirmed cases and 1,437 deaths.
- The Serum Institute of India has manufactured 620,000 doses of the vaccine in record time and supplied 4,000 investigational doses for the trial.
- The study team will continue recruiting volunteers, with preparations underway for further clinical studies in Uganda.
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
First human volunteer vaccinated against Bundibugyo strain of Ebola
Oxford
Vaccine
Ebola
Oxford Vaccine Group
the Serum Institute of India
the University of Oxford
Clinical Trial
Covid-19
the Democratic Republic of Congo
Uganda
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks